SCHEMBL1744992

SCHEMBL1744992

COC(=O)c1sc2ccccc2c1OCc1ccccc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.57
MAPK1 P28482 1/20 0.57
MAPT P10636 5/20 0.55
KDM4E B2RXH2 4/20 0.55
HPGD P15428 2/20 0.55
L3MBTL1 Q9Y468 3/20 0.54
KMT2A Q03164 7/20 0.52
ALDH1A1 P00352 5/20 0.52
GAA P10253 3/20 0.52
HSD17B10 Q99714 2/20 0.52
MEN1 O00255 1/20 0.52
GLA P06280 1/20 0.52
ALOX15 P16050 1/20 0.52
ATM Q13315 1/20 0.52
TDP1 Q9NUW8 2/20 0.51
SENP5 Q96HI0 3/20 0.47
SENP2 Q9HC62 3/20 0.47
SENP1 Q9P0U3 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPSR1 Q6W5P4 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5034495 0.83 SENP5 (0.59) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL15697530 0.81 LMNA (0.61) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL8913166 0.80 LMNA (0.60) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL1745439 0.80 LMNA (0.60) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL4603051 0.80 L3MBTL1 (0.45) LMNAMAPK1KDM4EL3MBTL1KMT2A
SCHEMBL9025214 0.78 LMNA (0.69) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL4632942 0.77 ALDH1A1 (0.56) LMNAMAPTKDM4EHPGDL3MBTL1
SCHEMBL1746851 0.76 L3MBTL1 (0.41) LMNAMAPTL3MBTL1KMT2AALDH1A1
SCHEMBL4651635 0.76 LMNA (0.55) LMNAMAPK1MAPTKDM4EHPGD
SCHEMBL31078467 0.76 LMNA (0.55) LMNAMAPK1MAPTKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR LMNA 4714/4885MAPK1 1667/4885MAPT 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.